A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Quizartinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Ambit Biosciences Corporation
- 16 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 16 Jan 2014 Planned End Date changed from 1 Aug 2013 to 1 Dec 2014 according to last checked against ClinicalTrials.gov record.
- 23 Jan 2013 Planned End Date changed from 1 Jun 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.